Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Other Non-Current Liabilities (2019 - 2025)

Atea Pharmaceuticals' Other Non-Current Liabilities history spans 7 years, with the latest figure at $6.8 million for Q3 2025.

  • Quarterly Other Non-Current Liabilities rose 9.58% to $6.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Sep 2025, up 9.58% year-over-year, with the annual reading at $6.4 million for FY2024, 10.39% up from the prior year.
  • Other Non-Current Liabilities came in at $6.8 million for Q3 2025, up from $6.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $6.8 million in Q3 2025 to a low of $29000.0 in Q2 2021.
  • The 5-year median for Other Non-Current Liabilities is $5.9 million (2021), against an average of $5.3 million.
  • The largest YoY upside for Other Non-Current Liabilities was 20617.24% in 2022 against a maximum downside of 11.41% in 2022.
  • Atea Pharmaceuticals' Other Non-Current Liabilities stood at $5.9 million in 2021, then dropped by 11.41% to $5.3 million in 2022, then rose by 9.57% to $5.8 million in 2023, then rose by 10.39% to $6.4 million in 2024, then rose by 6.91% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for AVIR's Other Non-Current Liabilities are $6.8 million (Q3 2025), $6.6 million (Q2 2025), and $6.5 million (Q1 2025).